- Home
- BAFN vs ALGS Comparison
BAFN vs ALGS Comparison
Compare BAFN & ALGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BAFN | ALGS |
|---|---|---|
| Founded | 1999 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.6M | 57.2M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | BAFN | ALGS |
|---|---|---|
| Price | $8.10 | $13.57 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $60.00 |
| AVG Volume (30 Days) | 6.7K | ★ 81.5K |
| Earning Date | 01-29-2026 | 11-06-2025 |
| Dividend Yield | ★ 1.98% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $58,931,000.00 | $2,646,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.40 | $3.76 |
| 52 Week High | $19.75 | $46.80 |
Technical Indicators
Market Signals| Indicator | BAFN | ALGS |
|---|---|---|
| Relative Strength Index (RSI) | 44.54 | 80.94 |
| Support Level | $7.90 | $9.10 |
| Resistance Level | $8.49 | $10.45 |
| Average True Range (ATR) | 0.12 | 0.75 |
| MACD | 0.07 | 0.38 |
| Stochastic Oscillator | 33.90 | 92.29 |
Price Performance
Historical ComparisonAbout BAFN BayFirst Financial Corp.
BayFirst Financial Corp is a bank holding company, it generates its revenue from interest on loans and the gain-on-sale income derived from the sale of loans into the secondary market. The company serves a broad spectrum of individuals, families, and small businesses, supported by national business lines in residential and SBA lending and technology platforms. The primary source of funding for its loans is deposits. BayFirst measures performance through net interest income after provision for loan losses, return on average assets, and return on average common equity, while maintaining appropriate regulatory leverage and risk-based capital ratios. The company has various segment such as Real Estate(Residential, Commercial, and Construction & Land), Commercial and Industrial, Consumer.
About ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.